PRAME and neoplasm: Both VLD and SLLs bind well to HLA-A2 molecules; thus, experiments with synthetic peptides were required to establish epitope specificity, as distinctions were not possible testing tumor cell lines that express endogenous PRAME protein, since both peptides can be presented simultaneously by tumor cells (unpublished observations).